药物遗传标记 在儿科急性淋巴细胞白血病治疗中
L Fishchuk1, Z Rossokha2, N Levkovych1
1Institute of Genetic and Regenerative Medicine, SI "National Scientific Center named after M.D. Strazhesko NAMS of Ukraine", Kyiv, Ukraine.
Experimental oncology
|March 6, 2026
概括
药物遗传标志物影响儿科急性淋巴细胞白血病 (ALL) 的治疗毒性和反应. 虽然TPMT和NUDT15具有临床实用性,但对其他标志物进行进一步研究是必要的,以个性化ALL治疗.
科学领域:
- 药物基因组学 药物基因组学
- 儿科瘤学 儿科瘤学
- 临床药理学 临床药理学
背景情况:
- 急性淋巴细胞白血病 (ALL) 是一种常见的儿童癌症,具有复杂的治疗方案.
- 化疗组合提高了疗效,但增加了毒性评估的挑战.
- 遗传变异可以解释ALL治疗期间药物反应和毒性的个体差异.
研究的目的:
- 审查和分析用于儿科ALL的药物的显著药物遗传标记.
- 评估这些标记物的临床实用性,以预测毒性和反应.
- 识别知识缺口和未来的研究方向,以个性化ALL治疗.
主要方法:
- 文献综述和对药物遗传标记物的分析.
- 专注于与 antracyclines,vincristine,glucocorticoids,L-asparaginase,methotrexate,化剂,6-mercaptopurine,cytarabine 和 etoposide 相关的标记物.
- 评估现有的临床实用性和正在进行的研究.
主要成果:
- TPMT和NUDT15是唯一的基因,在儿科ALL药物遗传学中具有确定的临床实用性.
- 大多数其他ALL药物的药物遗传标记仍在调查中.
- 在已识别的标志物的临床相关性存在显著的变化.
结论:
- 个性化治疗儿科ALL可以通过药物遗传学测试来推进.
- 进一步的研究对于验证标记物和将其纳入临床实践至关重要.
- 了解对药物反应的遗传影响是改善所有结果的关键.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
56
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
76
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
342
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
342
01:29Pharmacogenomics: Identification of New Drug Targets
55
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
304
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
304
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
49
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
49